Loading organizations...

Developing milk-inspired therapeutics for infectious diseases
Key people at Matrubials.
Matrubials was founded in 2018 by Carlito Lebrilla (Founder) and Bruce German (Founder) and David Mills (Founder) and Ishita Shah (Founder).
Matrubials is an anti-infectives company, focused on human milk peptides as therapeutics to address antimicrobial resistance and modern diseases. Currently the global rise in severe bacterial infections and the drying pipeline of effective treatments are burdensome for healthcare and economics. Sculpted by evolution, milk, first food for the newborn, provides an exemplary solution to address the nutritive and protective challenges an infant is faced with. The anti-pathogenic molecules from milk can be developed into therapeutics geared towards all-age diseases. Our first indication is bacterial vaginosis, a bacterial dysbiosis related inflammation that results in recurrent infections, disruption of homeostasis and long-term clinical complications in women of reproductive age, including but not limited to preterm births, fertility issues and increased rates of STDs. Our next inflection point is the evaluation of rapidly acting and selective candidate peptides in pre-clinical host impact and early safety studies, which can aid clinical and portfolio development towards topical applications.
Key people at Matrubials.
Matrubials was founded in 2018 by Carlito Lebrilla (Founder) and Bruce German (Founder) and David Mills (Founder) and Ishita Shah (Founder).
Matrubials is a biotech company developing milk-inspired therapeutics targeting infectious diseases, with a primary focus on antimicrobial resistance. Their lead product candidates are derived from human milk peptides—naturally evolved molecules that selectively kill pathogenic bacteria while preserving beneficial microbes. The company’s initial indication is bacterial vaginosis (BV), a common and recurrent vaginal infection linked to serious reproductive health complications. Matrubials aims to provide safer, more effective alternatives to traditional antibiotics, addressing the growing problem of drug-resistant infections. Beyond women’s health, they are expanding into skin health therapeutics using AI-driven drug discovery to accelerate development and market entry[1][2][3].
Founded in 2018 as a spin-out from the Foods for Health Institute at UC Davis, Matrubials was co-founded by Dr. Ishita M. Shah, an infectious disease expert with prior research experience at Genentech and Columbia University. The idea emerged from Dr. Shah’s research on the protective and nutritive properties of human milk, particularly its antimicrobial peptides. Recognizing the potential to replicate these peptides synthetically, the team focused on developing therapeutics that could address unmet needs in infectious disease treatment. Early traction included winning innovation awards, securing NIH SBIR grants, and acceptance into prominent accelerators like Y Combinator and Sacramento Growth Factory[1][2][4].
Matrubials is positioned at the intersection of biotech innovation and the urgent global challenge of antimicrobial resistance (AMR). As traditional antibiotics lose efficacy, there is a critical need for novel, selective anti-infectives. Milk-derived peptides represent a biomimetic approach that harnesses natural defense mechanisms, aligning with trends toward precision and host-friendly therapies. The company’s use of AI for drug discovery reflects the broader digitization of biotech R&D, enabling faster and more cost-effective development cycles. By focusing on women’s health and skin infections, Matrubials addresses large, underserved markets with significant clinical and economic burdens, potentially influencing future therapeutic paradigms in infectious disease management[1][2][3].
Looking ahead, Matrubials is advancing toward FDA approval for its first vaginal insert therapeutic, expected within the next few years, while simultaneously developing skin health products that may reach the market faster due to less stringent regulatory pathways. The company’s growth will be shaped by ongoing trends in combating AMR, increasing demand for microbiome-friendly treatments, and the integration of AI in drug development. As they expand their pipeline and validate clinical efficacy, Matrubials could become a key player in redefining anti-infective therapies inspired by natural biology, with broad implications for women’s health and beyond[2][3][5][6]. Their innovative approach ties back to the foundational insight that human milk’s evolved molecules offer a blueprint for next-generation therapeutics.